Photo of Manni Mohyuddin from patientpower.info
Jun 7, 2024, 14:45
Manni Mohyuddin on DREAMM-7
Manni Mohyuddin shared on X/Twitter:
“In DREAMM-7 (bela/bort/dex vs dara/bort/dex).
- Only 34% of pts len refractory.
- POLLUX trial showed PFS of 45 months with dara/len/dex
- Would bela/velcade/dex (PFS=37 mo) beat DRd for len sensitive patients?
Answer is clear:
If len/dara sensitive at relapse, use dara/len/dex!
I do not think we will get such results with Bela/bortezomib/dex in a US population that is increasing both Dara and Len refractory at first relapse.
PFS will likely be very modest.
Some food for a (controversial thought). How much PFS2 do we sacrifice with our current approach to treating myeloma?”
Source: Manni Mohyuddin/X
Dr. Manni Mohyuddin is an Assistant Professor at the Huntsman Cancer Institute, University of Utah, specializing in oncology. He is mainly interested in myeloma, supportive care, end-of-life management, and implementing cost-effective, evidence-based treatment strategies.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14